The Biostatistics Core provides collaborative services in the areas of biostatistics; programming, computation and data management; and data abstraction and medical records management. The 1.75 FTE biostatisticians will administer the core and collaborative in study and form design, perform interim analyses and monitoring of ongoing studies and experiments, and collaborate in analyses (including methodological work as needed), manuscript preparation and publication. The programming and computer group will have 3.6 FTE's to accomplish the following tasks: maintain a VAX cluster of computers (one 6310 and two 11/750's) with a 4 gigabyte disk farm and the ability to handle 40 simultaneous users, prepare data entry software and file structure for specific ALC projects, consult on the purchase, operation and problems of investigator PC's used for ALC projects, perform statistical software runs under the direction of the biostatisticians, program reporting software, and maintain current and archival datafiles both online and offline. The data abstraction unit consists of individuals with medical records expertise. These 7.1 FTE's spread among eleven individuals perform the following tasks: 1) abstract selected data points for the approximately 320 patients/year used in the grant proposal, 2) register patients on protocols (including randomized studies), and 3) maintain and run a research file room for the use of the ALC investigators. The unit has provided all of these services during the current 5 year grant. The biostatistical interaction is evidenced by the fact that biostatisticians have been coauthors on 64 ALC publications, including 17 in 1990.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA018029-20
Application #
3729173
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
20
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Deegan, Anthony J; Talebi-Liasi, Faezeh; Song, Shaozhen et al. (2018) Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med 50:183-193
Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515
Schmitt, Michael W; Pritchard, Justin R; Leighow, Scott M et al. (2018) Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res 24:5321-5334
Shaw, Bronwen E; Syrjala, Karen L; Onstad, Lynn E et al. (2018) PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer 124:841-849
Jamani, Kareem; Onstad, Lynn E; Bar, Merav et al. (2018) Quality of Life of Caregivers of Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2271-2276
Ogimi, Chikara; Xie, Hu; Leisenring, Wendy M et al. (2018) Initial High Viral Load Is Associated with Prolonged Shedding of Human Rhinovirus in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2160-2163
Salter, Alexander I; Pont, Margot J; Riddell, Stanley R (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131:2621-2629
Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2018) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:555-562
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313

Showing the most recent 10 out of 1845 publications